Background: Precision oncology programs using next-generation sequencing to detect predictive biomarkers are extending therapeutic options for patients with metastatic breast cancer (mBC). Regularly, based on the recommendations of the interdisciplinary molecular tumor board (iMTB), an inclusion in a clinical trial is not possible. In this case, the German health insurance system allows for the application of reimbursement for an off-label drug use. Here, we describe the current challenges and our experience with reimbursement of molecular therapies in mBC. Methods: A total of 100 applications for reimbursement of off-label therapies recommended by an iMTB were filed for patients with mBC, of which 89 were evaluable for this analysis. The approval rate was correlated with the molecular level of evidence of the respective therapy according to the National Center for Tumor Diseases (NCT) and European Society for Medical Oncology Scale for Clinical Actionability of molecular Targets (ESCAT) classification as well as with pretreatment therapy lines. Findings: Overall, 53.9% (48/89) of reimbursement applications were approved. Applications for therapies based on level of evidence m1 (NCT classification), tier I and II (ESCAT classification) had a significantly and clinically relevant increased chance of reimbursement, while a greater number of previous treatment lines had no significantly increased chance of approval, though a trend of approval toward higher treatment lines was detectable. Interpretation: Currently, the German jurisdiction seems to aggravate the clinical implementation of clinically urgently needed molecular therapies.

1.
Horak
P
,
Heining
C
,
Kreutzfeldt
S
,
Hutter
B
,
Mock
A
,
Hullein
J
et al
.
Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers
.
Cancer Discov
.
2021
;
11
(
11
):
2780
95
.
2.
Hlevnjak
M
,
Schulze
M
,
Elgaafary
S
,
Fremd
C
,
Michel
L
,
Beck
K
et al
.
CATCH: a prospective precision oncology trial in metastatic breast cancer
.
JCO Precis Oncol
.
2021
;
5
:
676
86
.
3.
Stenzinger
A
,
Edsjo
A
,
Ploeger
C
,
Friedman
M
,
Frohling
S
,
Wirta
V
et al
.
Trailblazing precision medicine in europe: a joint view by genomic medicine Sweden and the Centers for personalized medicine, ZPM, in Germany
.
Semin Cancer Biol
.
2022
;
84
:
242
54
.
4.
Leichsenring
J
,
Horak
P
,
Kreutzfeldt
S
,
Heining
C
,
Christopoulos
P
,
Volckmar
AL
et al
.
Variant classification in precision oncology
.
Int J Cancer
.
2019
;
145
(
11
):
2996
3010
.
5.
Mateo
J
,
Chakravarty
D
,
Dienstmann
R
,
Jezdic
S
,
Gonzalez-Perez
A
,
Lopez-Bigas
N
et al
.
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
.
Ann Oncol
.
2018
;
29
(
9
):
1895
902
.
6.
Veenstra
DL
,
Mandelblatt
J
,
Neumann
P
,
Basu
A
,
Peterson
JF
,
Ramsey
SD
.
Health economics tools and precision medicine: opportunities and challenges
.
Forum Health Econ Policy
.
2020
23
1
).
7.
Flaherty
KT
,
Gray
R
,
Chen
A
,
Li
S
,
Patton
D
,
Hamilton
SR
et al
.
The molecular analysis for therapy choice (NCI-MATCH) trial: lessons for genomic trial design
.
J Natl Cancer Inst
.
2020
;
112
(
10
):
1021
9
.
8.
Mangat
PK
,
Halabi
S
,
Bruinooge
SS
,
Garrett-Mayer
E
,
Alva
A
,
Janeway
KA
et al
.
Rationale and design of the targeted agent and profiling utilization registry study
.
JCO Precis Oncol
.
2018
;
2018
(
2
):
1
14
.
9.
Massard
C
,
Michiels
S
,
Ferte
C
,
Le Deley
MC
,
Lacroix
L
,
Hollebecque
A
et al
.
High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial
.
Cancer Discov
.
2017
;
7
(
6
):
586
95
.
10.
Worst
BC
,
van Tilburg
CM
,
Balasubramanian
GP
,
Fiesel
P
,
Witt
R
,
Freitag
A
et al
.
Next-generation personalised medicine for high-risk paediatric cancer patients: the INFORM pilot study
.
Eur J Cancer
.
2016
;
65
:
91
101
.
11.
Horak
P
,
Klink
B
,
Heining
C
,
Groschel
S
,
Hutter
B
,
Frohlich
M
et al
.
Precision oncology based on omics data: the NCT Heidelberg experience
.
Int J Cancer
.
2017
;
141
(
5
):
877
86
.
12.
Andre
F
,
Bachelot
T
,
Commo
F
,
Campone
M
,
Arnedos
M
,
Dieras
V
et al
.
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
.
Lancet Oncol
.
2014
;
15
(
3
):
267
74
.
13.
Zardavas
D
,
Maetens
M
,
Irrthum
A
,
Goulioti
T
,
Engelen
K
,
Fumagalli
D
et al
.
The AURORA initiative for metastatic breast cancer
.
Br J Cancer
.
2014
;
111
(
10
):
1881
7
.
14.
Maetens
M
,
Brown
D
,
Irrthum
A
,
Aftimos
P
,
Viale
G
,
Loibl
S
et al
.
The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group
.
NPJ Breast Cancer
.
2017
;
3
:
23
.
15.
Robert
NJ
,
Dieras
V
,
Glaspy
J
,
Brufsky
AM
,
Bondarenko
I
,
Lipatov
ON
et al
.
RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer
.
J Clin Oncol
.
2011
;
29
(
10
):
1252
60
.
16.
Kaufman
PA
,
Awada
A
,
Twelves
C
,
Yelle
L
,
Perez
EA
,
Velikova
G
et al
.
Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane
.
J Clin Oncol
.
2015
;
33
(
6
):
594
601
.
17.
Tegze
B
,
Szallasi
Z
,
Haltrich
I
,
Penzvalto
Z
,
Toth
Z
,
Liko
I
et al
.
Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance
.
PLoS One
.
2012
;
7
(
2
):
e30804
.
18.
Almendro
V
,
Cheng
YK
,
Randles
A
,
Itzkovitz
S
,
Marusyk
A
,
Ametller
E
et al
.
Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity
.
Cell Rep
.
2014
;
6
(
3
):
514
27
.
19.
Venkatesan
S
,
Swanton
C
.
Tumor evolutionary principles: how intratumor heterogeneity influences cancer treatment and outcome
.
Am Soc Clin Oncol Educ Book
.
2016
;
35
:
e141
9
.
You do not currently have access to this content.